Loading...
•
Dec 31, 2019
Akero Q4 2019 Earnings Report
Akero reported fourth quarter and full year financial results for the period ending December 31, 2019.
Key Takeaways
Akero Therapeutics reported on their progress in clinical and manufacturing development, highlighting the advancement of AKR-001 and a strong cash position to support its continued development.
Continued clinical and manufacturing progress for Akero.
Rapid progress combined with a strong cash position.
AKR-001 has the potential to become a cornerstone of NASH treatment.
AKR-001 is currently being evaluated in the ongoing Phase 2a BALANCED study.
Akero
Akero
Forward Guidance
Akero's forward-looking statements involve risks and uncertainties, and actual results may differ materially from expectations. The company does not undertake any obligation to update these statements.